Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Oral nano vitamin D supplementation eases disease activity, severity in ulcerative colitis

17 Nov 2019

Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.

The investigators assessed the effect of oral nano vitamin D3 supplementation on disease activity in active UC (UC disease activity index [UCDAI] ≥3) by randomizing patients with active UC and vitamin D <40 ng/mL to receive either oral nano vitamin D (60,000 IU/dx8 d) or placebo.

Participants were then evaluated for disease activity (UCDAI scores, C-reactive protein, erythrocyte sedimentation rate and faecal calprotectin) at baseline and at 4 weeks. The response was defined as a 3-point reduction in UCDAI score at 4 weeks and decrease in inflammatory markers.

The median vitamin D levels rose from 15.4 to 40.83 mg/dL in the vitamin D group (p≤0.001) and marginally from 13.45 to 18.85 mg/dL (p=0.027) in the control group. Response was more prevalent among vitamin D patients as compared with controls (53 percent vs 13 percent; p=0.001).

Increase in vitamin D levels led to reductions in UCDAI score (p≤0.001; ρ=–0.713), C-reactive protein (p0.001; ρ=–0.603) and calprotectin (p=0.004; ρ=–0.368). Patients who achieved the target vitamin D level of >40 ng/mL (n=17) were more likely to reach a 3-point reduction in UCDAI (80 percent vs 20 percent; p≤0.001) and a decrease in severity grade from 60 percent to 35 percent (p=0.038).

Moreover, vitamin D administration (odds ratio [OR], 9.17, 95 percent confidence interval [CI], 2.02–41.67) and baseline histologic activity (OR, 1.92, 95 percent CI, 1.2–3.08) were independently associated with response.

“Vitamin D possesses anti-inflammatory properties and could be beneficial in UC,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.